Abstract
Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.
Original language | English (US) |
---|---|
Pages (from-to) | 1449-1455 |
Number of pages | 7 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 23 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2014 |
Keywords
- Biologic
- Human
- IL-6
- Lupus nephritis
- Monoclonal antibody
- Sirukumab
- Systemic lupus erythematosus
- Therapy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)